{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-24-000062","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2024-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.308760+00:00","generated_at":"2026-05-29T04:09:21.496399+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Krystal Biotech reports positive initial clinical data for inhaled gene therapies KB408 (AATD) and KB407 (CF)","bullets":["KB408: single dose increased lung AAT from 85nM to 729nM in AATD patient; active neutrophil elastase dropped >50%.","Gene delivery confirmed: 39% of airway cells AAT-positive post-dose vs 0% at baseline.","KB407 for CF: Phase 1 CORAL-1 granted conditional sanctioning by CFF TDN; safe and well tolerated.","KB407 enrolling Cohort 3 (4 daily doses); data expected 1H 2025.","No serious adverse events in either program; all adverse events mild to moderate and transient."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-24-000062","json":"https://secwatch.observer/filing/0001711279-24-000062.json","markdown":"https://secwatch.observer/filing/0001711279-24-000062.md","text":"https://secwatch.observer/filing/0001711279-24-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127924000062/0001711279-24-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127924000062/krys-20241212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T04:09:21.496399+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}